Can a new injection calm severe eczema in kids?
NCT ID NCT07767253
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This trial is testing an experimental drug called 611 in children aged 2 to 12 with moderate-to-severe atopic dermatitis, a common skin condition that causes itchy, inflamed skin. The drug is designed to block a specific immune signal that drives the inflammation behind eczema. The study will compare the drug against a placebo to see if it can improve skin symptoms like redness and itching.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 611, an experimental antibody that blocks a key immune signal involved in allergic inflammation
- What this could lead to
- If successful, this could provide a new treatment option for children with moderate-to-severe atopic dermatitis, potentially reducing itch and skin flares.
- What could go wrong
- This is an early-stage trial in a specific age group, and the drug may not work as well as hoped or may cause side effects. Results from this trial will need confirmation in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, 100045, China
-
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing Municipality, 100050, China
-
Dermatology Hospital, Southern Medical University
Guangzhou, Guangdong, 510091, China
-
Hunan Children's Hospital
Changsha, Hunan, 410007, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Real-World dupixent: does it live up to the hype for eczema?
- Scientists hunt for biological clues to severe childhood eczema
- Can a drug calm severe eczema itch when the rash is mild? a new study investigates
- Eczema drug nemolizumab put to the vaccine test
- New eczema drug enters first human tests
- Eczema drug study pulled before it started